Interferon alpha (Hayashibara/Otsuka/Mochida)

N/A

Report date: 2023/09/19 10:06:13

Base Information

Drug NameInterferon alpha (Hayashibara/Otsuka/Mochida)
Drug Alias NameIFN-alpha lozengesNatural human lymphoblastoid interferon-alphaVeldonaMOR-22
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionImmunomodulatorsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsCoughPulmonary FibrosisPulmonary Disease, Chronic Obstructive +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanTurkey
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHayashibara
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNobel PharmaceuticalsAinos IncTexas Tech University Health Sciences Center
Active IndicationsCarcinoma, Renal CellLeukemia, Myelogenous, ChronicHepatitis C +[5] 
Inactive IndicationsCoughPulmonary FibrosisPulmonary Disease, Chronic Obstructive +[8] 

Other Information

ATC CodeL03AB01
Related LinksN/A